Navigation Links
OptiNose Completes Series C-1 Financing
Date:8/4/2014

YARDLEY, Pa., Aug. 4, 2014 /PRNewswire/ -- OptiNose, a specialty pharmaceutical company, announced today that it has completed a Series C-1 round of financing led by existing investors. Since obtaining Series C financing in 2010, OptiNose has successfully developed AVP-825, a product that, once approved, will be used for the treatment of migraines. OptiNose out-licensed the North American marketing rights for AVP-825 to a partner and jointly submitted a New Drug Application with the U.S. FDA earlier this year. In parallel with that program, OptiNose has actively pursued the significantly larger development program of OPN-375, a new product with applications in the treatment of serious chronic nasal inflammatory diseases.

Sriram Venkataraman, a director of OptiNose and a partner at Avista Capital Partners, said, "We are pleased with the progress of the clinical development programs to date and are committed to supporting the OptiNose team further as they execute on their clinical and commercial priorities, especially the development of the major new product OPN-375."

"With this latest round of financing, we are well-positioned to take the actions necessary to maximize the potential of our second product, OPN-375, which we believe will be a transformational breakthrough product in a large market with significant unmet need," said Peter Miller, Chief Executive Officer of OptiNose. "I am proud of the OptiNose team and the progress we have made together to date. I am also very excited about the future, as we continue late-phase clinical research, prepare commercial supply chain, and engage in pre-commercialization efforts around OPN-375."

About OPN-375

OPN-375 uses OptiNose's patented technology to deliver a highly effective and well-understood topical steroid medication (fluticasone) into the nasal cavity in a deeply distributed manner that improves u
'/>"/>

SOURCE OptiNose
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. OptiNose Receives Grant to Fund Nose-to-Brain Research in Autism Spectrum Disorders
2. OptiNose mottar stipend for nese-til-hjerne-forskning innen spektrumet for autismesykdommer
3. MGC Diagnostics Corporation Completes Acquisition of MediSoft SA
4. Auxilium Pharmaceuticals, Inc. Announces XIAFLEX Milestone: Partner Asahi Kasei Pharma Corporation Completes Regulatory Submission For Dupuytrens Contracture In Japan
5. Cardioxyl Pharmaceuticals Successfully Completes First Clinical Trial For Heart Failure Drug CXL-1427
6. Glide Pharma Completes Successful Proof-of-Concept Study with Novel Solid Dose Formulation of Octreotide
7. TeraMedica Completes one of the Worlds Largest VNA Installations in New South Wales, Australia
8. Seres Health Completes Enrollment in a Clinical Study for SER-109 in Recurrent Clostridium difficile Infection and Announces Positive Preliminary Data
9. Verus Healthcare Completes Over 85 Acquisitions
10. Virobay Completes $8 Million Series B Preferred Stock Financing
11. Valeant Pharmaceuticals Completes Sale Of Filler And Toxin Assets To Galderma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... MONMOUTH JUNCTION, N.J. , Dec. 22, 2014 ... immunotherapy company marketing its CytoSorb® blood purification technology ... cardiac surgery patients in 28 countries worldwide, today ... Di Russo , MD, FACS, as its Senior ... 2015. Dr. Di Russo ...
(Date:12/22/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/h3xm6q/us ... Self-monitoring Blood Glucose Market" report to their offering. ... This market insight focuses on the developments in the ... States . Reimbursement analysis and the effects of ... more than 73 SMBG meters have been performed, based ...
(Date:12/22/2014)... , Dec. 22, 2014  ConvaTec, a privately-held medical ... has been appointed Interim Chief Executive Officer of the ... succeeds Ken Berger .  "The Board of Directors ... leading ConvaTec over the past three years," said ... Directors.  "We are confident that the company is well ...
Breaking Medicine Technology:CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5US Self-monitoring Blood Glucose Market 2ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2
... received 510(k) clearance from the U.S. Food and Drug ... spot scanning. Spot scanning is a proton therapy delivery ... the tumor by using thousands of small individual beamlets ... Intensity Modulated Proton Therapy (IMPT). XiO, Elekta,s ...
... 3, 2010 Halozyme Therapeutics, Inc. (Nasdaq: ... commercializing products targeting the extracellular matrix , today ... serve as president and CEO, effective immediately. Jonathan E. ... of the board of directors to pursue other opportunities. ...
Cached Medicine Technology:Elekta Receives FDA 510(k) Clearance for XiO Software to Plan Spot Scanning for Proton Therapy 2Halozyme Therapeutics Realigns Management 2Halozyme Therapeutics Realigns Management 3
(Date:12/24/2014)... Dec. 24, 2014 (HealthDay News) -- A lab technician ... may have been exposed to the Ebola virus in ... And up to a dozen other lab workers are ... Wednesday afternoon. The possible exposure occurred Monday when ... sample of the potentially lethal virus to another CDC ...
(Date:12/24/2014)... (PRWEB) December 24, 2014 Gluten, a ... on those who have an intolerance to gluten, causing ... gas, bloating, migraine headaches, joint pain and fatigue. For ... diet plans that deliver safe and fast weight ... that trigger a gluten allergy reaction. These gluten free ...
(Date:12/24/2014)... Jacksonville, Florida (PRWEB) December 24, 2014 The ... a safer place to raise families. In-Vest USA ... those who protect us – our first responders. Today, these ... law enforcement officers by providing them with body armor through ... like the tragic shootings that happened this past week in ...
(Date:12/24/2014)... Dallas, Texas (PRWEB) December 24, 2014 ... COC Industry is a professional and in-depth research ... the report introduces COC basic information, including its ... policy analysis, news analysis, etc. This report also ... structure etc. Production is separated by regions, technology ...
(Date:12/24/2014)... FL (PRWEB) December 24, 2014 There’s a ... days. With the Republican Party now in control of the ... again for the Affordable Care Act. A lawsuit has been ... delays of certain provisions in the ACA have resulted in ... Also, a Supreme Court hearing will take place to weigh ...
Breaking Medicine News(10 mins):Health News:CDC Monitors Lab Worker for Possible Ebola Exposure 2Health News:Diet Doc Adds Gluten Free Diet Plans to Their Stable of Specialized Weight Loss Programs 2Health News:Diet Doc Adds Gluten Free Diet Plans to Their Stable of Specialized Weight Loss Programs 3Health News:The Healthy Home Company and In-Vest USA Team Up to Save the Lives of Law Enforcement 2Health News:COC/ Cyclic Olefin Copolymer Market: Global 2015-2020 Forecasts & Research Report Now at DeepResearchReports.com 2Health News:COC/ Cyclic Olefin Copolymer Market: Global 2015-2020 Forecasts & Research Report Now at DeepResearchReports.com 3Health News:Steven Gerst MD Discusses How, Amid Political Opposition, Court Challenges, and a New Open Enrollment Period, the Affordable Care Act still Relies on Health Informatics 2Health News:Steven Gerst MD Discusses How, Amid Political Opposition, Court Challenges, and a New Open Enrollment Period, the Affordable Care Act still Relies on Health Informatics 3
... Travel Advantage Network , one of the nation,s ... Susan G. Komen for the Cure , the global leader ... pin sales and a Jeans Day, where employees purchase the ... employees raised $729 for Susan G. Komen for the Cure, ...
... 22 McAuley Ministries, the new grant-making arm of ... first grant... and the recipient is the YMCA of ... the construction of a green rooftop terrace for the ... new Thelma Lovette YMCA touches several of McAuley Ministries ...
... Aurora Health Care announced today that,the physicians ... join Aurora Medical Group. , ... Paul,Guzzetta, M.D., and Mark Plumb, M.D. All are board-certified ... specializes and is,board-certified in the treatment of sleep disorders. ...
... In the year following Hurricane Katrina, the health of ... of a national sample of older adults not affected ... researchers at the Johns Hopkins Bloomberg School of Public ... most powerful and deadliest hurricanes in U.S. history. Hurricane ...
... the founder and longtime director of the HIV advocacy/education ... Institute of Allergy and Infectious Diseases (NIAID) Director,s Special ... against HIV/AIDS. , Mr. Delaney in 1985 ... public policy information and advocacy organization based in San ...
... , Montreal, January 22, 2009 The ... that preventive treatment with high doses of inhaled corticosteroids ... asthma attacks triggered by colds. Dr. Francine Ducharme, assistant ... Center and a pediatrics professor at the Universit de ...
Cached Medicine News:Health News:Grassroots Group Gets Travel Advantage Network Support 2Health News:YMCA of Greater Pittsburgh Receives $500,000 from McAuley Ministries for New Hill YMCA Roof 2Health News:YMCA of Greater Pittsburgh Receives $500,000 from McAuley Ministries for New Hill YMCA Roof 3Health News:Midwest Pulmonary and Critical Care Associates Will Join Aurora Medical Group 2Health News:Decline in health among older adults affected by Hurricane Katrina 2Health News:NIAID honors AIDS activist Martin Delaney 2Health News:New treatment reduces severity of asthma attacks in preschoolers 2